Form 4: CytoDyn Director Tanya Durkee Urbach Receives Stock Options
SEC Form 4 Filing
Director Tanya Durkee Urbach of CytoDyn Inc. was granted non-qualified stock options for 800,000 shares on October 28, 2024, as part of her annual compensation.
Summary
- Tanya Durkee Urbach, a director of CytoDyn Inc., received a grant of non-qualified stock options on October 28, 2024.
- The options allow her to purchase 800,000 shares of CytoDyn's common stock at an exercise price of $0.13 per share.
- This grant represents her annual compensation for the fiscal year 2025 and is part of the company's 2012 Equity Incentive Plan.
- 266,664 shares vested immediately, with the remaining shares vesting in equal monthly installments from October 2024 through May 2025.
- Urbach also provided a Limited Power of Attorney effective February 1, 2024, authorizing individuals including Jacob Lalezari, Mitchell Cohen, Tyler Blok, and Nathan Fox to execute forms related to her securities transactions.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain overtly positive or negative information, hence a neutral sentiment score.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
- The vesting schedule incentivizes continued service through May 2025.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service from the director.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
- The size of the grant and vesting schedule are typical for companies of CytoDyn's size and stage of development.
- Comparing CytoDyn's equity incentive plan to those of similar biotech companies like Amgen or Gilead would provide a more detailed benchmark.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's success.
- Employees may see the grant as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| February 1, 2024 | Effective date of the Limited Power of Attorney granted by Tanya Urbach. |
| October 28, 2024 | Date of the stock option grant to Tanya Durkee Urbach. |
| October 28, 2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.